Seoul, South Korea - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was today awarded the Best Biologics CRO Award at a ceremony as part of 11th Biologics Manufacturing Korea, the 6th Cell & Gene Therapy World East Asia, and the 3rd BioLogistics World Korea conferences (29th – 30th June 2022) which attract more than 300 representatives from Korea’s top biopharmas, vaccine manufacturers, and biologics companies.

Novotech Country Managing Director Sanghee Kim said the Korea team was extremely pleased to receive this award in recognition of the clinical excellence provided to clients in the biologics sector.

Novotech Vice President Global Head Clinical Services Yooni Kim also said:

“Novotech’s Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.”

Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, New Zealand, South Korea, Greater China, Southeast Asia, India, South Africa and the US.

Novotech CEO Dr. John Moller said:

“The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest-growing clinical trial destination with China being the leading location for new trials followed by the US.

Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes.

The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.”

Clients will receive a seamless service, with a unified approach to systems and SOPs,” Moller said.

Media contact

关于 Novotech Novotech-CRO.com

Novotech(诺为泰)成立于 1997 年,立足亚太,面向全球,是专业的生物技术合同研究组织(CRO)。

诺为泰因其在行业内的突出贡献而备受赞誉,曾荣获多项殊荣,其中包括 2023 年 CRO 领导力奖 (CRO Leadership Award 2023) 、2023 年亚太地区细胞与基因治疗临床试验卓越奖 (Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023)和自 2006 年以来蝉联亚太地区合同研究组织年度公司奖 (Asia-Pacific Contract Research Organization Company of the Year Award)。

诺为泰是一家包含实验室、Ⅰ期临床中心、药物开发咨询服务和专业FDA法规服务的临床CRO,拥有超5,000 项临床项目经验,包括Ⅰ期至Ⅳ期临床试验。Novotech专注于服务在亚太、美国与欧洲等地进行临床试验的生物技术客户。Novotech目前在全球34个办公地点共拥有3000多名员工。

要了解更多信息或与专家团队成员交谈,请访问 www.Novotech-CRO.com